What is the significance of a Herpes Simplex Virus Type 2 (Herpes II) Antibody (IgG) level of 8.39, indicating a condition of Hyperimmune response to Herpes Simplex Virus Type 2?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2025 • View editorial policy

From the Guidelines

The result of 8.39 for Herpes II Ab (IgG) indicates a positive test for herpes simplex virus type 2 (HSV-2) antibodies, confirming past exposure and infection with genital herpes, as the index value is significantly above the positive threshold (typically >1.1) 1. This suggests established immunity, and no immediate treatment is necessary if you're not experiencing symptoms, as this result indicates a chronic infection rather than an acute outbreak.

Key Considerations

  • The diagnosis of genital herpes can be realized using type-specific molecular or virologic tests when genital ulcers are present, and type-specific serologic test to detect antibody when lesions are not present 1.
  • For the management of genital herpes, episodic antiviral therapy or suppressive antiviral therapy can be used, with medications like acyclovir, valacyclovir, or famciclovir helping to manage symptoms 1.
  • It's essential to understand that HSV-2 remains dormant in nerve cells between outbreaks and can be transmitted even without symptoms, so using barrier protection during sexual activity is advised 1.
  • You should inform sexual partners about your HSV-2 status to allow them to make informed decisions about protection.

Treatment Options

  • For acute outbreaks, medications like acyclovir (400mg three times daily for 7-10 days), valacyclovir (1g twice daily for 7-10 days), or famciclovir (250mg three times daily for 7-10 days) can help manage symptoms.
  • For frequent outbreaks (more than 6 per year), daily suppressive therapy with acyclovir (400mg twice daily), valacyclovir (500mg daily), or famciclovir (250mg twice daily) may be recommended 2.

Important Notes

  • The sensitivity of HSV-2 serologic testing is high, estimated at 92%, but false-negative tests may occur after acquisition of the virus during the window period, which may be up to 12 weeks 2.
  • Type-specific HSV serologic assays differentiate between HSV-1 and HSV-2, and the gold standard for HSV serologic testing is Western blot/immunoblot assays, which target antibodies to several HSV antigens in addition to glycoprotein G 2.

From the Research

Herpes II Ab.(IgG) Results

  • The result of 8.39 for Herpes II Ab.(IgG) indicates the presence of IgG antibodies against Herpes Simplex Virus Type 2 (HSV-2) in the patient's blood 3.
  • IgG antibodies are typically detected in individuals who have been infected with HSV-2 in the past, and their presence can indicate a current or past infection 3.

Interpretation of Results

  • A study published in the Indian Journal of Pathology & Microbiology found that HSV-2 IgG detection had a sensitivity of 73.33% in recurrent genital herpes diagnosis, indicating that the presence of IgG antibodies can be a useful marker for diagnosing recurrent HSV-2 infections 3.
  • However, the same study found that HSV-2 IgG detection had a specificity of 85.71%, indicating that some individuals without HSV-2 infection may also test positive for IgG antibodies 3.

Management and Treatment

  • Daily suppressive therapy with antiviral medications such as valacyclovir or acyclovir can reduce the frequency and severity of HSV-2 recurrences, as well as decrease the risk of transmission to others 4, 5.
  • A study published in the Journal of Medical Virology found that daily acyclovir chemosuppression reduced mean IgG antibody concentration by 10% from baseline values, indicating that antiviral therapy may also affect the immune response to HSV-2 4.

Risk of Transmission

  • The risk of transmitting HSV-2 to others can be reduced through the use of antiviral medications, condoms, and avoidance of sexual contact during recurrences 6, 5.
  • A study published in The Journal of Infectious Diseases found that daily suppressive therapy with acyclovir did not decrease the risk of HSV-2 transmission to susceptible partners in HIV-1-infected individuals, highlighting the need for more effective prevention strategies 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.